# Sonrai Analytics

> Sonrai Analytics is a reviewed AI agency in Belfast, United Kingdom, listed in the AIAgencies.eu register and last assessed 2026-09-08.

Canonical page: https://www.aiagencies.eu/agency/sonrai-analytics
Generated: 2026-09-24 · Curated by Gabor Kiss · No paid placements — inclusion, score, and rank are never sold.

## Facts
- Location: Belfast, United Kingdom
- Website: https://sonraianalytics.com
- Hourly rate: not published
- Team size: 10-49
- Founded: 2018
- Services: AI Development, AI Consulting
- Industries: Healthcare
- LinkedIn: https://uk.linkedin.com/company/sonrai-analytics

## About
Sonrai Analytics is a Belfast AI and data-science company working in precision medicine, building machine-learning and computational-pathology systems for pharma and diagnostics clients on its own analysis platform.

## Documented clients
Documented engagements: IV Bioholdings, Axis Bio, and Precision Medicine Centre, Queen's University Belfast. All 3 carry a source URL on file.

## Curator assessment
Reviewed 2026-09-08 by Gabor Kiss against published evidence.

Two named clients describe the same practice from opposite ends: IV Bioholdings' CEO credits the engagement with turning legacy RNA-Seq and PCR data into a validated biomarker case, and Axis Bio's co-founder describes custom apps that replaced Excel for a preclinical CRO, with a traffic-light check flagging anomalies such as unexpected body-weight changes.

The regulated work is what separates this from general data science—AI IVD medical devices for MSI testing in colorectal cancer and PD-L1 tumour proportion scoring in non-small cell lung cancer, built with the Precision Medicine Centre at Queen's University under an NHS AI Award—but read the results section closely: the devices are described as ready for submission to a notified body, not yet CE-marked under IVDR.

Six people are named on the team page, four of them with doctorates, and delivery is described as scientist-led with no handoffs; the platform percentages quoted elsewhere on the site (52% faster biomarker discovery, 57% acceleration on mechanism-of-action studies) carry no client attached.

The weaker fit is anyone outside precision medicine: the whole practice is oncology, multi-omics and computational pathology, with no general-purpose AI delivery shown.

### Key strengths
- Regulated-AI work is the practice rather than a claim: IVD devices for MSI and PD-L1 scoring built toward EU IVDR conformity assessment with Queen's University's Precision Medicine Centre
- Named client executives on the record—IV Bioholdings' CEO and Axis Bio's co-founder—each describing what the engagement changed
- Six named people on the team page, four with doctorates, and delivery described as scientist-led rather than handed to an account team

### Good to know
- The IVD devices are described as ready for submission to a notified body, not approved—ask where each device sits in conformity assessment today
- Client outcomes are qualitative (investment case strengthened, client satisfaction); the percentage figures elsewhere are the platform's own claims—ask for a program with measured endpoints
- No rate is published and the team is 10-49—anchor on the European range on our rate index and ask how many programs run concurrently

---
Source: AIAgencies.eu — the curated register of European AI agencies. Rate provenance: "agency-confirmed" = disclosed via submission or claimed profile; "directory-listed" = Clutch or two agreeing B2B directories (lone unverified sources are never written). Full method: https://www.aiagencies.eu/methodology · Rate index: https://www.aiagencies.eu/rates